Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity Modulated Radiation Therapy After Surgery for the Treatment of Endometrial or Cervical Cancer

Overview

Información sobre este estudio

The purpose of this study is to evaluate whether proton radiation therapy (proton RT) reduces acute gastrointestinal toxicities at the end of treatment compared to intensity modulated radiation therapy (IMRT).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

    •  
  • Age ≥ 18 years old.
  • Histologically confirmed diagnosis of cervical or endometrial cancer..
  • Must have undergone an open or robotic hysterectomy (total abdominal, vaginal, radical, or total laparoscopic) for carcinoma of the cervix or endometrium.
  • History and physical prior to registration.
  • Documentation of history of:
    • Smoking status;
    • Pelvic infection;
    • Pelvic Inflammatory Disease;
    • Endometriosis.            
  • Planned to receive either proton or Intensity-Modulated Radiation Therapy (IMRT) radiation treatment, with use of rectal balloon, at an IRB-approved Mayo Clinic site.
  • Plan for radiation therapy (RT) to pelvis with or without para-aortic lymph node irradiation.
  • If received high-dose chemotherapy prior to registration, last dose must have been given ≥ 21 days prior to start of RT .       
  • CBC performed within 21 days prior to registration.
  • CT, MRI, PET/CT, or PET/MRI for staging before registration; may be pre-op or post-op.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0-2.
  • Provide written informed consent.
  • Willing to complete QOL questionnaires.

Exclusion Criteria: 

  • Receiving external beam boost dose during RT.
  • Distant metastases.
  • No gross disease at time of RT.
  • Histology of endometrial stromal sarcoma, leiomyosarcoma, melanoma or small cell carcinomas.
  • Patients who exceed the weight/size limits of the treatment table.
  • Patients with active irritable bowel disease.
  • Positive or close surgical margins (≤ 3 mm).
  • Prior RT to the pelvis.
  • Planned to receive inguinal node RT.
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
  • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note that HIV testing is not required for entry into this protocol.  The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be immunosuppressive.
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
      • Severe, active co-morbidity defined as follows:
        • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
        • Transmural myocardial infarction within the last 6 months;
        • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
      • Other major medical illness which requires hospitalization or precludes study therapy at the time of registration.
  • Patients unwilling to have rectal balloon placed on a daily basis during RT.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Allison Garda, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Daniel Trifiletti, M.D.

Abierto para la inscripción

Contact information:

Kayla Lane M.P.H.

(904) 953-3588

Rodriguez.Kayla1@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Sujay Vora, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20503346

Mayo Clinic Footer